PTIX

Protagenic Therapeutics, Inc. [PTIX] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

PTIX Stock Summary

Top 10 Correlated Stocks

PTIX

In the News

PTIX Financial details

Company Rating
-
Market Cap
6.39M
Income
-5.01M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
1
Optionable
No
Shortable
Yes
Earnings
15 May 2024
P/E
-0.95
Forward P/E
-
PEG
-0.25
P/S
-
P/B
0.9
P/C
-
P/FCF
-1.39
Quick Ratio
4.12
Current Ratio
4.2
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-1.15
EPS next Y
-
EPS next Q
-
EPS this Y
38.55%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
18.75%
-
-
-
-
SMA20
-3.7%
SMA50
-48%
SMA100
-58.73%
Inst Own
-
Inst Trans
-
ROA
-73%
ROE
-69%
ROC
-0.96%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.68-2.32
52W High
-
52W Low
-
RSI
38.03
Rel Volume
6.71
Avg Volume
10.43K
Volume
70.01K
Perf Week
-10%
Perf Month
-18.15%
Perf Quarter
-64.62%
Perf Half Y
-63.7%
-
-
-
-
Beta
0.383
-
-
Volatility
0.02%, 0.03%
Prev Close
-10%
Price
0.225
Change
-10.36%

Something similar

Top by Market Cap
BRYN.DE
AAPL
BRK-A
FB2A.DE
LLY.SW
Same Sector
AKRO
YCBD-PA
2389.HK
2633.HK
CNCE
Top Correlated Stocks
WALD
KW
Similar Market Cap
LCTC
GRNQ
VEEE
BFRI
PHE.TO

Company Profile

Healthcare Biotechnology
  • Volume Average 10.43K
  • Market Capitalization 6.39M
  • Employee 1
  • CEO Dr. Garo H. Armen Ph.D.
  • Headquarters New York,NY,US
  • IPO Date 2021-04-27
  • Website https://www.protagenic.com

Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound is PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. The company is based in New York, New York.